Custom Search

Rituximab News

FDA Approves Two New Indications for Rituxan(R) (Rituximab) in Patients With Non-Hodgkin's Lymphoma

Rituxan Improves Progression-Free Survival When Used in Combination with CVP Chemotherapy as a First-Line Treatment in Patients with Follicular Non-Hodgkin's Lymphoma.

Rheumatoid Arthritis

This study will evaluate the effectiveness of retreatment with rituximab in people with active rheumatoid arthritis (RA) who are receiving methotrexate (MTX) and who have had an inadequate response to tumor necrosis factor (TNF)...

Biogen Idec Reports Second Quarter 2006 Results

Cambridge, Mass., Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology company with leading products and capabilities in oncology, neurology and immunology, today reported its second quarter 2006 results.

Genta Receives Special Protocol Assessment from FDA for Confirmatory Trial of Genasense(R) Plus Chemotherapy in Chronic Lymphocytic Leukemia

Randomized Trial to Evaluate Fludarabine and Rituximab with or without Genasense in Previously Untreated Patients

Thousands to Benefit from Launch of Novel Rheumatoid Arthritis Therapy

Current Treatments Failing Nearly 30% of Patients with Severe RA : MabMabTheraŽ(rituximab) Offers New Hope

Displaying results 11 to 15 out of 24

< Previous






Next >

Use of this site is subject to the following terms of use